Similar articles

• A new orally active, aminothiol radioprotector-free of nausea and hypotension side effects at its highest radioprotective doses.

  Soref CM, Hacker TA, Fahl WE. Soref CM, et al. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):e701-7. doi: 10.1016/j.ijrobp.2011.11.038. Epub 2012 Feb 11. Int J Radiat Oncol Biol Phys. 2012. PMID: 22330992
• A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer.

  Anné PR, Curran WJ Jr. Anné PR, et al. Semin Radiat Oncol. 2002 Jan;12(1 Suppl 1):18-9. doi: 10.1053/srao.2002.31358. Semin Radiat Oncol. 2002. PMID: 11917279 Clinical Trial.
• Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy.

  Cassatt DR, Fazenbaker CA, Bachy CM, Hanson MS. Cassatt DR, et al. Semin Radiat Oncol. 2002 Jan;12(1 Suppl 1):97-102. doi: 10.1053/srao.2002.31382. Semin Radiat Oncol. 2002. PMID: 11917293
• Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine.

  Cassatt DR, Fazenbaker CA, Kifle G, Bachy CM. Cassatt DR, et al. Semin Oncol. 2002 Dec;29(6 Suppl 19):2-8. doi: 10.1053/sonc.2002.37355. Semin Oncol. 2002. PMID: 12577236 Review.
• Improved tolerability of amifostine with rapid infusion and optimal patient preparation.

  Boccia R. Boccia R. Semin Oncol. 2002 Dec;29(6 Suppl 19):9-13. doi: 10.1053/sonc.2002.37358. Semin Oncol. 2002. PMID: 12577237 Review.